A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer

CONCLUSIONS: Lenvatinib at a starting dose of 24 mg/day significantly improved progression-free survival and objective response rate in Chinese patients with RR-DTC versus placebo. There were no new or unexpected toxicities. Results are consistent with those from SELECT involving patients with RR-DTC.PMID:34326132 | DOI:10.1158/1078-0432.CCR-21-0761

Source: Clinical Cancer Research - July 30, 2021 Category: Cancer & Oncology Authors: Xiangqian Zheng Zhengang Xu Qinghai Ji Minghua Ge Feng Shi Jianwu Qin Feng Wang Guang Chen Yuan Zhang Rui Huang Jian Tan Tao Huang Sijin Li Zhongwei Lv Yansong Lin Zhuming Guo Tomoki Kubota Takuya Suzuki Hiroki Ikezawa Ming Gao Source Type: research